About Hanmi

한미약품은 창조와 도전을 기치로 신약개발에 매진하는 R&D중심 제약기업입니다.



  • Dec Formulation patent for stabilization of targeted anticancer drug granted
  • The 5th Hanmi Proud MD award, Dr. Muyeol Park (Goramdola hospital)
  • Hanmi and Kainos collaborate on new drug development
  • Nov ppreciation plaque from the Korean Red Cross
  • Fixed-dose combination 'Irbestin' collaboration with Sanofi
  • Oct Medicine donation for North Korean flood victims
  • US patent granted for next generation antimycotics formulation
  • Sep Medicine donation to Pyongyang Mankyungdae Univ. Hospital
  • Aug LAPS-Exendin for type 2 diabetes, selected as a government supported project
  • Launched low-dose erectile-dysfunction medication
  • July Launches PalPal Chew Tab. 50mg
  • July Selected as a Pharmaceutical Company of Innovation, by Ministry of Welfare
  • AprIn-licensing deal with SK Biopharmaceuticals for development and commercialization of Diazepam Nasal Spray
  • Beijing Hanmi, accredited as 'R&D Center' by Beijing Government
  • Received the CE mark for Hyalrheuma from UK SGS
  • MarHanmi-GSK, Collaboration agreement for FDC development
  • Launched Koennasal spray (Hyalu acid+Dexpantenol)
  • Hanmi Holdings changed name from Hanmi Holdings to Hanmi Science
  • New anti-obesity, diabetes drug (HM47000), chosen as new drug development program by government
  • FebThe 11th Hanmi literature awards
  • License agreement for anti obesity botanical drug (ALS-L1023)
  • 'Amosartan' published in international academic journals (BMC, AJCD, Clinical Therapeutics)
  • JanLAPS-GCSF, Collaboration with Spectrum (US)
  • Supply agreement for 13 OTC drugs with MEIC(Mongolia)
  • LAPS-GCSF, Collaboration with Spectrum (US)